Biochemical Society Transactions (2018)
https://doi.org/10.1042/BST20180420

Review Article

The chemistry of the vitamin B3 metabolome

Mikhail V. Makarov[1], Samuel A.J. Trammell[2] and Marie E. Migaud[1]

[1]Mitchell Cancer Institute, University of South Alabama, 1660 Springhill Ave, Mobile 36604, AL, U.S.A.; [2]Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Correspondence: Marie E. Migaud (mmigaud@health.southalabama.edu)

The functional cofactors derived from vitamin B3 are nicotinamide adenine dinucleotide (NAD^+), its phosphorylated form, nicotinamide adenine dinucleotide phosphate ($NADP^+$) and their reduced forms (NAD(P)H). These cofactors, together referred as the NAD(P)(H) pool, are intimately implicated in all essential bioenergetics, anabolic and catabolic pathways in all forms of life. This pool also contributes to post-translational protein modifications and second messenger generation. Since NAD^+ seats at the cross-road between cell metabolism and cell signaling, manipulation of NAD^+ bioavailability through vitamin B3 supplementation has become a valuable nutritional and therapeutic avenue. Yet, much remains unexplored regarding vitamin B3 metabolism. The present review highlights the chemical diversity of the vitamin B3-derived anabolites and catabolites of NAD^+ and offers a chemical perspective on the approaches adopted to identify, modulate and measure the contribution of various precursors to the NAD(P)(H) pool.

Introduction

Niacin and niacinamide, also known as nicotinic acid (NA) and nicotinamide (Nam), are the better known forms of vitamin B3 [1,2]. Along with tryptophan (trp), they are biosynthetic precursors to nicotinamide adenine dinucleotide (NAD^+), nicotinamide adenine dinucleotide phosphate ($NADP^+$) and their respective reduced forms (NAD(P)H), altogether referred as the NAD(P)(H) pool. The vitamin B3 metabolome includes the biosynthetic precursors of NAD^+ (anabolites; Table 1a), the cofactors derived from NAD^+ (i.e. the NAD(P)(H) pool; Table 1a) and the derivatives generated through catabolic processes (catabolites; Table 1b) [3–8]. Altogether, the NAD^+-derived cofactors are central to cellular homeostasis and growth through their roles in intermediary metabolism, mitochondrial respiration, the Krebs' cycle, ATP production, reactive oxygen species generation and inhibition, and additional roles in post-translational protein modifications, protein regulation and second messengers' generation [9–16]. Sub-optimal intracellular levels of these cofactors yield to cellular dysfunction, while acute vitamin B3 deficiency leads to pellagra [17,18], a debilitating and deadly disease still endemic in some regions of the world where malnutrition is common place. In more affluent countries, clinical vitamin B3 deficiency is due to poor food choices, adverse drug reactions, alcoholism and infectious or autoimmune diseases [19–22]. There are several additional excellent publications covering in detail the biological and physiological roles of the NAD(P)(H) pool and that of its biosynthetic precursors [23–30]. The present review covers the breadth of the vitamin B3 metabolome and presents an overview of the tools used to modulate the NAD(P)(H) pool and therefore the vitamin B3 metabolome in biological systems with a focus on mammalian systems. First, the known vitamin B3 metabolites (anabolites and catabolites) and the biosynthetic pathways to NAD(P)(H) will be summarized. A brief foray in the chemical and chemoenzymatic routes to NAD^+ precursors will then follow along with an overview of isotopically labeled metabolic NAD^+ intermediates, which have been used to report on the vitamin B3 metabolomic profiles..

Received: 26 August 2018
Revised: 14 October 2018
Accepted: 17 October 2018

Version of Record published:
17 December 2018

Biochemical Society Transactions (2018)
https://doi.org/10.1042/BST20180420

Table 1a Chemical structures and abbreviations of the anabolites constituting the vitamin B3 metabolome

Anabolites of the vitamin B3 metabolome, precursor to the NAD(P)(H) pool

Anabolic species					
VitaminB3	Nucleobase	Nucleoside	Nucleotide	Dinucleotide	Reduced dinucleotide
Niacin containing derivatives					
	NA	NAR	NAMN	NAAD, NAADP	
Nicotinamide containing derivatives					
	Nam	NR	NMN	NAD^+, NADP	NADH, NADPH

Abbreviations: NA, niacin/nicotinic acid; Nam, niacinamide/nicotinamide; NR, nicotinamide riboside; NAR, nicotinic acid riboside; NAMN, nicotinic acid mononucleotide; NMN, nicotinamide mononucleotide; NAAD, nicotinic acid adenine dinucleotide; NAADP*, nicotinic acid adenine dinucleotide phosphate; NAD^+, nicotinamide adenine dinucleotide; $NADP^+$, nicotinamide adenine dinucleotide phosphate; NADH, nicotinamide adenine dinucleotide reduced form; NADPH, nicotinamide adenine dinucleotide phosphate reduced form. *Generated via a yet unknown mechanism.

The chemistry of the NAD(P)(H) pool

The anabolites and catabolites of the vitamin B3 metabolome

Once generated from vitamin B3 derivatives via independent biosynthetic pathways, NAD^+ can be converted to its reduced form NADH via redox processes or to its phosphorylated form $NADP^+$, which, in turn, can enter redox processes to generate its reduced form, NADPH. Alternatively, NADH can be phosphorylated to NADPH. This constitutes the anabolic pathways to the NAD(P)(H) pool. Upon a range of biochemical and chemically driven processes, the components of the NAD(P)(H) pool are converted to nicotinamide or to catabolites which are either eliminated through excretion or recycled. The following describes these components in greater detail.

Vitamin B3 anabolites

Niacin (NA) and niacinamide (Nam) fall under the vitamin B3 denomination [1]. Intracellularly, NAD^+ is generated from dietary vitamin B3 or trp (Figure 1) with the contribution made by the latter, known as the kynurenine pathway, varying greatly between species and organs [31–36]. Via the kynurenine pathway, biosynthetic precursors to NAD^+ include kynurenine, 3-hydroxykinurenine, 3-hydroxyanthranilate and quinolinate, leading to nicotinic acid mononucleotide (NAMN) [37]. NAMN is also an NAD^+ anabolite through the Preiss–Handler pathway, which uses NA [38], while nicotinamide mononucleotide (NMN) is generated in the salvage pathway, which uses Nam. Additional NAD^+ anabolites include nicotinamide riboside (NR), nicotinic acid (NAR) and nicotinic acid adenine dinucleotide (NAAD) [8,39,40].

Vitamin B3 functional catabolites

NAD^+ and $NADP^+$ are substrates of enzymes capable of cleaving the glycosidic linkage between the northern ribose of the dinucleotide and nicotinamide, and replacing the latter with water, nucleophilic nucleobases or side chains of peptidic residues (e.g. hydroxyl or carboxylate) [41–49]. Unless chemical hydrolysis occurs, this cleavage is a finely orchestrated nucleophilic enzymatic process, leading to an exquisitely specific derivative. These derivatives are unique with regard to the biology they regulate [50]. NAADP is generated by an as-yet undiscovered biosynthetic pathway either from NAAD or from $NADP^+$, regulating intracellular Ca^{2+} signaling processes [51]. The cyclic form of adenosine diphosphoribose, cADPR, produced by a cyclase [5], specifically mobilizes Ca^{2+} from ryanodine receptors [52], while its linear form, ADPR (adenosine diphosphoribose), generated from NAD^+ by

Table 1b Chemical structures and abbreviations of the catabolites constituting the vitamin B3 metabolome

Catabolites of the vitamin B3 metabolome



Abbreviations: *N*-Me-Nam, *N*-methyl nicotinamide or trigonellinamide; *N*-methyl-NA, *N*-methyl nicotinic acid or trigonelline; *N*-Oxide-Nam, *N*-oxide nicotinamide; *N*-Me-4PY, *N*-methyl-4-pyridone-3-carboxamide; *N*-Me-2PY, *N*-methyl-2-pyridone-4-carboxamide; 4PYR, 1-β-D-ribofuranosyl 4-pyridone-3-carboxamide; 4PYR-MP (*n* = 1), 1-β-D-ribofuranosyl 4-pyridone-3-carboxamide monophosphate; 4PYR-DP (*n* = 2), 1-β-D-ribofuranosyl 4-pyridone-3-carboxamide diphosphate; 4PYR-TP (*n* = 3), 1-β-D-ribofuranosyl 4-pyridone-3-carboxamide triphosphate; NADO, 4-pyridone-3-carboxamide adenine dinucleotide; NADPO, 4-pyridone-3-carboxamide adenine dinucleotide phosphate; 1,2-NADH, 1,2-dihydronicotinamide adenine dinucleotide; 1,2-NADPH, 1,2-dihydronicotinamide adenine dinucleotide phosphate; 1,6-NADH, 1,6-dihydronicotinamide adenine dinucleotide; 1,6-NADPH, 1,6-dihydronicotinamide adenine dinucleotide phosphate; NADHX, adenosine 5′-(trihydrogen diphosphate), *P′* → 5′-ester with 1,4,5,6-tetrahydro-6-hydroxy-1-β-D-ribofuranosyl-3-pyridinecarboxamide also known as 6-hydroxylated nicotinamide adenine dinucleotide reduced form. NADPHX, adenosine 5′-(trihydrogen diphosphate), *P′* → 5′-ester with 1,4,5,6-tetrahydro-6-hydroxy-1-β-D-ribofuranosyl-3-pyridinecarboxamide phosphate also known as 6-hydroxylated nicotinamide adenine dinucleotide phosphate reduced form. cADPR, cyclic adenosine diphosphoriboside; ADPR, adenosine diphosphoribose; ADPRP, adenosine diphosphoribose phosphate; PAR, poly adenosine diphosphoriboside; Ac-ADPR, acetyl adenosine diphosphoribose; Suc-ADPR, succinyl adenosine diphosphoribose; acyl-ADPR, acyl adenosine diphosphoribose.

glycohydrolases, promotes Ca^{2+} cellular uptake [53]. Unlike ADPR itself, acylated forms of ADPR are products of NAD^+- dependent post-translation modification catalyzed by sirtuins [10,26,54] hydrolyzed to ADPR by esterases [55]. Finally, the polymeric forms of ADPR, product of PARP enzymes, either covalently bound to proteins or free in solution, act as major complex recruiting agents in DNA repair [56–58].

Vitamin B3 catabolites

Many catabolic pathways are responsible for the loss of vitamin B3-derived cofactors and of their anabolites. Upon high NA intake, excess NA is converted to nicotinuric acid (NUA, Table 1b) in a phase 2 metabolic process when conjugated to glycine [59]. Excess Nam is readily oxidized to *N*-oxide-Nam (Table 1b) by cytochrome P450 [60,61]. Yet, under standard dietary conditions, the bigger contributor to vitamin B3 catabolism in human physiology is the methylation of Nam, leading to *N*-methyl-Nam (*N*-Me-Nam; Table 1b). The formation of *N*-methyl-Nam requires *S*-adenosylmethionine. Therefore, in conjunction with homocysteine, *N*-methyl-Nam is a reporter of both the 1-carbon pathway efficacy and the vitamin B3 dietary status [62,63].

Biochemical Society Transactions (2018)
https://doi.org/10.1042/BST20180420



Figure 1. Precursors to NAD$^+$.

Blue box: PRPP-dependent NAD$^+$ biosynthetic pathways; Green box: PRPP and vitamin B1, B2 and B6-independent pathways; PRPP, 5-phospho-1-pyrophosphoriboside; vitamin B1, thiamine; vitamin B2, riboflavin; vitamin B6, pyridoxine; NA, niacin/nicotinic acid; Nam, niacinamide/nicotinamide; NR, nicotinamide riboside; NAR, nicotinic acid riboside.

Trigonelline is *N*-methyl nicotinic acid, found abundantly in fenugreek and thought to be generated during coffee bean processing [64,65]. Trigonelline is also a catabolite found in tissues but less often measured [66] and for which the physiological properties remain unexplored. Oxidation of circulating *N*-methyl-Nam by aldehyde oxidase yields *N*-methyl-4-pyridone3-carboxamide (*N*-Me-4PY) and *N*-methyl-2-pyridone-5-carboxamide (*N*-Me-2PY) [6,67–69]. Much confusion exists in the literature as to the nomenclature of these two entities. The relative production of these catabolites is species-specific as well as driven by age and health status [70]. *N*-Me-2PY has been described as a uremic toxin because of the correlation between its abundance in blood and kidney disease states [71]. Critically, these two pyridones are produced systemically [72,73]. There, *N*-Me-2PY is thought to be an inhibitor of PARP function at physiologically relevant concentrations [67,74,75]. Another catabolite of vitamin B3 is *N*-ribosyl-3-carboxamide 4-pyridone (4PYR, Table 1b). This ribosylated pyridone is also found abundantly in circulation in uremic patients. Importantly, it is easily converted to its nucleotide forms (4PYR-MP, 4PYR-DP, 4PYR-TP, Table 1b) or adenylated to generate pyridone adenine dinucleotide species [NAD(P)O, Table 1b] [76–82]. Both the phosphorylated forms of 4PYR and its dinucleotide forms are endogenously generated. The synthesis of NADPO has been shown to occur as a side-reaction on NAD(P)$^+$ catalyzed by flavin-dependent oxidases, such as ferrodoxin reductase [83–85]. *In vitro*, the nucleotide forms show substantial ability to inhibit ATP-dependent kinases, while the dinucleotides are inhibitors of NAD(P)$^+$-dependent metabolic redox enzymes at physiologically relevant concentrations [76,86]. A similar class of NAD(P)$^+$ catabolites capable of inhibiting key metabolic enzymes are hydroxylated NAD(P)H (NAD(P)HX, Table 1b). The generation of these catabolites, which occurs chemically, is sufficiently critical to warrant a repair mechanism in all forms of life and the regeneration of NAD(P)H as accumulation of these catabolites causes central metabolomic perturbations [87,88]. Finally, other even less explored NAD(P)H catabolites are the 1,2-NAD(P)H and the 1,6-NAD(P)H [89]. These isomers can be mistaken for the α-anomeric forms of NAD(P)H [90–92] and are excellent inhibitors of isolated NAD(P)H-dependent redox enzymes. Renalase has been shown to re-oxidize these NAD(P)H isomers *in vitro*. It can then be viewed as a NAD(P)H repair enzyme directly affecting intracellular metabolism [93].

Overall, except for *N*-Me-Nam and *N*-Me-2PY, the catabolites of the NAD(P)(H) metabolome are rarely accounted for in metabolomic studies [94–96]. Furthermore, these compounds react readily under standard analytical conditions used for cell and tissues metabolomic measurements unless special care is applied and therefore go undetected. As such, an in-depth account of the detection protocols of the vitamin B3 metabolome is warranted but is beyond the scope of this review. Furthermore, mammalian cells have in place at least two known repair mechanisms to control dinucleotidic catabolite levels, renalase and NAD(P)HX dehydratase/

epimerase [87,88,93]. Dysregulation of such repair processes and accumulation of these catabolites surely impacts cellular homeostasis. Yet, the function, regulation and impact of the multiple vitamin B3 repair mechanisms have been vastly under-explored.

Biochemical pathways known to sustain the NAD(P)(H) pool

Notably, tryptophan, NA and Nam employ three convergent pathways which require molar equivalents of 5-phospho-1-pyrophosphoriboside (Scheme 1; PRPP) to convert quinolinic acid and NA to nicotinic acid adenine dinucleotide (NAAD) or Nam to NAD^+ (Scheme 1) [34].

While cofactors derived from riboflavin (vitamin B2) [97] and pyridoxine (vitamin B6) [98] are required by enzymes of the kynurenic pathway to generate quinolinic acid from tryptophan, $NADP^+$ and thiamine (vitamin B1) diphosphate are cofactors required for the synthesis of PRPP from glucose 6-phosphate [36]. This highlights the dependency of the NAD(P)(H) biosynthetic pathways on the bioavailability of three other metabolic cofactors, all derived from water soluble B-vitamins.

Along with NA, Nam and trp, NAR and NR are also precursors of NAD^+ (Scheme 1). Noticeably, QA, NA and Nam require phosphoribosylation as means of biosynthetic activation to NAMN [99] and NMN [100–102], while NR and NAR require phosphorylation by a specific kinase (Scheme 1) [8,39,103,104]. NAMN and NMN are biosynthetic intermediates to NAAD and NAD^+, following an adenylyl transfer (Scheme 1) [105–109]. NAAD, acting as a pre-NAD^+ storage pool [40], is converted to NAD^+ by a ligase (NADS) (Scheme 1) [35,110]. $NADP^+$ is generated from NAD^+ by NAD^+ kinase for which NADH is a weak substrate yielding NADPH [111]. It must be noted that while NR, NAR and NMN are PRPP-independent precursors to the



Scheme 1. Detailed biosynthetic pathways to the NAD(P)(H) pool components.

trp, tryptophan; Gln, glutamine; PRPP, 5-phosphoriboside pyrophosphate; NAPRT, nicotinic acid phosphoribosyl transferase; NamPRT, nicotinamide phosphoribosyl transferase; NMNAT, nicotinamide mononucleotide adenylyl transferase; NRK, nicotinamide riboside kinase; NADS, nicotinamide adenine dinucleotide synthase; NADK, nicotinamide adenine dinucleotide kinase; NADHK, NADH kinase; NQO2: *N*-ribosyldihydronicotinamide : quinone reductase 2.

Biochemical Society Transactions (2018)
https://doi.org/10.1042/BST20180420

NAD^+, they are only molar equivalent precursors to NAD^+. It is the generation of Nam through NAD^+ consuming enzymes and its recycling to NAD^+ which enables sustained NAD^+ levels [112]. To sustain increased NAD^+ levels through NR supplementation, NRK, NMNAT and NamPRT (nicotinamide phosphoribosyl transferase; Scheme 1) must be functional, with turn-over in excess of that of Nam methylation by NNMT and cellular export mechanisms.

It is only recently that NR and NMN, both found in milk [113,114], have gained recognition as nutraceutical precursors of NAD^+. NR supplementation in cell-based assays was evidenced to boost the NAD(P)(H) pool with a specific effect on the mitochondrial pool and function. Supplementation with NA and Nam, while critical in acute vitamin B3 deficiency, does not demonstrate the same physiological outcomes compared with that of supplementation with NR or NMN [7,15,34,94], indicative of additional controlling factors, such as intracellular biodistribution, expression of key biosynthetic enzymes and/or bioavailability of PRPP. To explore the parameters controlling functionalization and conversion of these NAD^+ precursors and their biological endpoints in cell-based assays as well as in animals, an extensive synthetic program has been implemented over the past 50 years.

Accessing biosynthetic precursors of NAD^+

NA and Nam can be readily obtained from bacterial broth, foodstuffs or generated from petroleum sources [1]. They are now widely available commercially along with some more clinically focused versions and formulations [115]. The ribosylated forms of NA or Nam have required the development of more substantial synthetic routes.

Enzymatic syntheses

NR may be prepared enzymatically from NAD^+ and NMN by using snake venom phosphodiesterase and subsequent transformation of NMN to NR with prostatic monoesterase [116] or with 5′-nucleotidase [117]. Alternatively, NR can be generated from α-D-ribose-1-phosphate and Nam using purine nucleoside phosphorylase and sucrose phosphorylase [118]. There are only few reports in the literature describing the efficient chemical generation of NMN from NR [119–121]. In general, this process is often low yielding and associated with difficulties in removing phosphate contaminants. As such, enzymatic conversions with isolated NRK or whole cell production have been explored, but they too remain challenging. Accessing NAR has been even less explored. Yet, the generation of NAMN from NMN using a new cross-linked deamidase aggregate biocatalyst has been reported [122]. This offers new opportunities for a facile access to NAR via enzymatic routes using phosphatases such as 5′-nucleotidase [8].

Chemical syntheses of nicotinoyl ribosides and derivatives

Two main synthetic strategies have been developed to access NR salt forms (NR^+X^-) (Figure 2). One proceeds via a reaction between Nam or derivative **A** and a peracylated (halo)-D-ribofuranoside **B** resulting in acylated intermediate **C** that is subsequently converted into the desired NR^+X^- salt. This approach was also applied for the synthesis of NAR (NAR zwitterion). The other proceeds via the condensation of *N*-(2,4-dinitrophenyl)-3-carbamoylpyridinium salt **D** with derivatives of D-ribofuranosylamine **E** [120]. To date, the first approach has proved the most efficient in terms of overall yields and chemo-selectivity. We will summarize advances made with this first approach.

Two anomeric α- and β-forms of NR (α-C and β-C; Figure 2) can be generated by glycosylation reactions with the stereochemical outcome of the synthesis being dependent on the nature and stereochemical position of the leaving group X, nature of the substituents at amide nitrogen atom in Nam and conditions of glycosylation, such as solvent and temperature. Because only the β-form of NR or NAR is of biochemical relevance, the most valuable synthetic methods offer β-stereoselectivity.

The first chemical syntheses of NR salts (NR^+X^-) was described by Todd and coworkers [123,124] and entailed the glycosylation of nicotinamide (Nam) **1a** with either 1-bromo-2,3,5-tri-*O*-acetyl-D-ribofuranose to yield the bromide salt, 1-chloro-2,3,5-tri-*O*-acetyl-D-ribofuranose to yield the triacetylated chloride salt or 1-chloro-2,3,5-tri-*O*-benzoyl-D-ribofuranose to yield the tribenzoylated chloride salt. The halosugars were obtained from 1,2,3,5-tetra-*O*-acetyl-D-β-ribofuranose (**2a**) or 1-*O*-acetyl-2,3,5-tri-*O*-benzoyl-D-β-ribofuranose (**2b**) [125]. Such chemistry resulted in the generation of both pyridinium riboside anomers, with the best results in terms of β-/α-anomer stereoselectivity obtained when chlorosugars were used as precursors. Removal



Figure 2. Synthetic routes to nicotinamide riboside (NR^+X^-).

of the protecting groups in anhydrous methanol saturated with dry ammonia at 0°C yielded NR^+Cl^- as a 4 : 1 mixture of β- and α-anomers [124]. Low temperature was required to minimize Nam release (Scheme 2).

While several routes and optimization studies have been conducted [126] since the first synthetic route development, the most versatile uses tetra-acylated ribosides and TMSOTf as a catalyst [127,128]. Sauve and coworkers improved on the method and reported a very efficient one-pot procedure for the synthesis of β-NR from ethyl nicotinate [129,130]. Both routes generate the triflate salt forms of NR. The triflate salts, deemed



Scheme 2. Synthetic sequence to 1-β-D-ribofuranoside nicotinamide chloride.

Biochemical Society Transactions (2018)
https://doi.org/10.1042/BST20180420

unsuitable for pharmacological use, must be exchanged for pharmaceutically acceptable anions. Anion exchange either by liquid/liquid extraction [131] or by treatment with ion exchange resin such as using Amberlite IRA400-Cl have been successfully applied to generated NR^+Cl^- [132]. Oxidation of the reduced form of NR **7** on charcoal in the presence of protic salts, such as ammonium salts NH_4X^-, is an alternative method to anion exchange resulting in different salt forms of NR^+X^-. Acylated NR-triflate and acylated NAR prepared via mechanochemical methods, reduced to the acylated 1,4-dihydronicotinamide and dihydronicotinoyl riboside, can be readily extracted in pure form in organic solvents (Scheme 3) [133]. The reduced forms of NR **6a-b** and NAR are stable to Brönsted bases and, therefore, the acyl groups can be removed at room temperature at increased rates [134,135]. 1,4-Dihydronicotinamide riboside derivatives may be also oxidized with hexachloroacetone or cobalt(II) acetate in the presence of hydrogen peroxide. The later process requires removal of cobalt cations with QuadraSil AP resin [136].

Chemical reduction in *N*-substituted pyridinium salts results in three possible isomeric products: 1,2-, 1,4- and 1,6-dihydropyridines (DHP) as illustrated in Figure 3 for corresponding dihydro-1-β-D-ribofuranosyl-3-pyridinecarboxamides.

Reduction in pyridinium salts to dihydropyridines has been extensively reviewed in the literature [137–140]. Sodium borohydride ($NaBH_4$) and sodium dithionite ($Na_2S_2O_4$) are the most commonly used reducing agents to reduce NAD(P), NMN and NR. However, these reagents are not equivalent. $Na_2S_2O_4$ regioselectively reduces NAD^+ to 1,4-dihydronicotinamide adenine dinucleotide (NADH), and NR to the 1,4-3-carboxamide dihydropyridinyl riboside, while reduction in NAD^+ and NR^+ with $NaBH_4$ or milder hydride-based reducing agents results in a mixture of the 1,2-, 1,4- and 1,6-isomers.

Synthesis of pyridones

While the hydroxylated forms of 1,4-3-carboxamide dihydropyridinyl riboside derivatives (e.g. NAD(P)HX) are readily generated from the ribosylated species, the pyridone-derived catabolites (N-Me-2/4-PY, 4-PYR, NAD(P)O, 4-PYR-M/D/TP; Table 1b) require chemical syntheses. 4-Pyridone-3-carboxamide (4PY) and 2-pyridone-5-carboxamide (2PY) are generated from 4-chloro-3-carboxypyridine and 2-hydroxy-5-cyanopyridine, respectively [79]. These can then be used to prepare the nucleosides [79,141]. Critically, the nucleotide- and dinucleotide-derived pyridones are only prepared on analytical scale, generated as enzymatic side-reaction products [142].



Scheme 3. Synthesis of the reduced form of NR as a synthetic intermediate to NR.



Figure 3. Reduction in derivatives of NR^+X^- into corresponding NRH derivatives.

Synthesis of isotope-labeled NAD^+ precursors (isotopomers and isotopologues)

Decaying and stable isotope-labeled derivatives [143–146] have been used to study metabolic pathways and biodistribution processes. Combining separation to detection and quantification allows for complex product distributions to be measured. To differentiate between biosynthetic components and pathways of the NAD(P)(H) pool, anabolites incorporating different profiles of stable isotopes can be used if their incorporation into NAD^+ leads to versions of NAD^+ which can be differentiated by mass (MS) or fragmentation patterns (MS^2). Here, enter two critical definitions: that of isotopomers which are molecules which vary in the position of labeled atom, such as 2′-^{2}H-NR versus 1′-^{2}H-NR and isotopologues which are molecules which differ by containing different isotopes, such as ^{2}H-NR versus ^{13}C-NR. These isotopically labeled compounds will possess different exact molecular mass and/or fragments' exact mass.

Presently, the rationale applied to selecting appropriate isotopologues is driven by the question being asked and the levels of the isotopically labeled derivatives to be detected. Bioavailability and biodistribution studies in animals are often addressed using decaying isotopomers. Combined to liquid chromatography, this highly sensitive method differentiates between the bio-transformed radio-isotopically labeled products, e.g. [147]. Furthermore, the uniformly labeled NAD^+ is commercially available and amenable to chemoenzymatic transformations. For instance, radio-isotopically labeled NAD^+ can be converted to its $NADP^+$ parent by NAD^+ kinase [148]. It is also reduced enzymatically to NADPH [148]. These can be used as starting materials in some of the enzymatic processes described below.

Non-decaying isotopomers provide the necessary versatility to interrogate fluxes if the building blocks and products can be traced with enough statistical confidence at levels above natural isotopic abundance. For instance, to establish in mammals whether NR was directly converted to NMN, or hydrolyzed to Nam prior to it being incorporated into NMN, the use of a doubly labeled isotopomer of NR was used [94]. This isotopomer incorporated one heavier isotope on the nicotinamide ring and one heavier isotope on the furanose. The glycosidic breakage led to mono-labeled NAD^+, while the direct incorporation led to doubly labeled NAD^+ being detected. In cell work study, this type of multi-site labeling informs on the regulation of the biosynthetic pathways and of the turn-over of NAD^+ by consuming and biosynthetic enzymes [34,40,107].

Isotopically labeled forms of Nam, NA and trp are available commercially and can thus be selected at will. Similarly, ribosylated derivatives, for which isotope labels may be incorporated into the sugar residue (^{2}H, ^{3}H, ^{18}O, ^{13}C and ^{14}C isotopes) and the nicotinamide or nicotinic core (^{18}O, ^{13}C, ^{14}C and ^{15}N isotopes), or both (Figure 4), require dedicated chemoenzymatic or chemical syntheses.

Decaying isotopically labeled NAD^+ anabolites, such as synthetic tritiated nucleotides and ^{32}P-containing ATP, have been combined to chemoenzymatic preparations to allow for the efficient generation of radiolabeled

Biochemical Society Transactions (2018)
https://doi.org/10.1042/BST20180420



Figure 4. General representation of isotope-labeled NR derivative; illustrative labeled sites are shown by colored asterisks.

NAD(P)(H) pools [149–155]. The enzymatic methods allow preparation of not only NR derivatives labeled in the Nam core but in the ribosyl moiety as well when labeled phosphoribosyl pyrophosphate (PRPP) is used. An example of this methodology is found in work of *Kašarov and Moat* describing preparation of [*carbonyl*-^{14}C]NR from corresponding ^{14}C-labeled NAD$^+$ catalyzed by enzymes from *Proteus vulgaris* OX-19 [156]. Saunders et al. [117] describe the preparation of [*carbonyl*-^{14}C]NR and [4-^{3}H]NR by the treatment of corresponding radiolabeled NMN with 5′-nucleotidase. Chemical synthesis of tritium-labeled NR and subsequent enzymatic synthesis of tritium-labeled NMN as well as corresponding [2′-^{3}H]-NAD$^+$ are described in work of Cen and Sauve [157], which also describes the synthesis of NAD$^+$ containing ^{18}O-label in the NR portion of the molecule and originating from [5-^{18}O]glucose. Bull et al. [158] describes the chemical synthesis of deuterium-labeled [1′-^{2}H]NR$^+$Br$^-$ and [1′-^{2}H]NMN. Once purified, this was used to prepare [1′-^{2}H]NAD$^+$ enzymatically, which was then enzymatically converted to [*carbonyl*-^{14}C,1′-^{2}H]NAD$^+$ with [*carbonyl*-^{14}C]Nam. In a series of papers by Schramm et al. dealing with the enzymatic synthesis of [^{3}H,^{14}C] NAD$^+$ isotopomers, the authors used [2-^{3}H]-, [5-^{3}H]-, [6-^{3}H]-, [2-^{14}C]- and [6-^{14}C]glucose and nicotinic acid to generate corresponding [1′-^{3}H]-, [2′-^{3}H]-, [4′-^{3}H]-, [5′-^{3}H]-, [1′-^{14}C]-, [5′-^{14}C]NAD$^+$; they also describe preparation of ^{15}N-labeled NAD$^+$ isotopologues, such as [1′-^{14}C,1-^{15}N]NAD$^+$ and [5′-^{14}C,1-^{15}N]NAD$^+$ (primed numbers indicate atomic locations in the ribosyl residue of NR part of NAD$^+$), using ^{15}N-labeled NA as a source of the label [159–162]. The enzymatic synthesis of [^{14}C]NR was achieved from unlabeled NAD$^+$ and [carbonyl-^{14}C] Nam in the presence of ADP-ribosylcyclase to give ^{14}C-NAD$^+$, followed by treatment with phosphodiesterase I and alkaline phosphatase [163].

While extremely sensitive, detection of radiation-emitting entities requires special laboratory set-up and therefore limits its use by the wider research community. Detection of non-decaying isotopic modifications are less sensitive but rely on more generally adopted protocols [145]. Yet, accurate measurements of the vitamin B3 metabolome in biological systems have been limited by the chemical availability of chemical standards and tailor-made vitamin B3 metabolites. However synthetic efforts have been undertaken towards achieving higher availability of labeled and non-labeled standards for an increased coverage, characterization and quantification of the metabolome. The use of isotopically labeled vitamin B3 metabolites combined to powerful targeted metabolomic analytical methods has proved particularly suited to improving our knowledge of vitamin B3 both at cellular and organismal levels, allowing rapid translational discoveries [34,164]. This has been enabled by dramatic advances in the field of mass spectroscopy, metabolomics and large data set management along with an increased access to molecules purposefully incorporating isotopes that enable their detection and quantification as well as inform of their modifications.

According to the approach described by Tran et al. [163], [^{13}C,^{18}O]NR can be generated from [U-^{13}C] glucose and NA enzymatically converted to [^{13}C]NAAD containing fully ^{13}C-labeled ribosyl residue in NAR part of the NAAD molecule. This synthesis requires usage of 10 enzymes, along with ATP, phospho(enol)pyruvate, NADP$^+$ and α-ketoglutarate. In the second — again enzymatic — step, purified ^{13}C-labeled NAAD was transformed to corresponding [^{13}C]NAD$^+$ by NAD$^+$ synthetase. Then, purified [^{13}C]NAD$^+$ was incubated with [^{18}O]Nam (prepared by chemical reaction of 3-cyanopyridine with ^{18}O-water) in the presence of ADP-ribosylcyclase to give [^{13}C,^{18}O]NAD$^+$ that was subsequently degraded by using phosphodiesterase I and alkaline phosphatase to quantitatively afford [^{13}C,^{18}O]NR. Furthermore, the enzymatic synthesis of ^{18}O-labeled NAD$^+$ from non-labeled NAD$^+$ can be achieved using glycohydrolase/cyclase CD38 and ^{18}O-nicotinamide (20-fold excess) [165]. Mills et al. [105] used double-labeled NMN prepared via a procedure based on the work of Lee et al., while Ratajczak et al. mention the synthesis of ^{18}O-labeled NR from [^{18}O]Nam and subsequent synthesis of ^{18}O-labeled NNM by phosphorylation with NRK1 [94,107]. Chemical sequences described above

were applied to generate [^{18}O]NR from ^{18}O-labeled Nam and [2′-^{2}H,*carbonyl*-^{13}C]NR generated from the 2′-^{2}H-1,2,3,5-tetra-*O*-acetyl-β-D-ribofuranose and [*carbonyl*-^{13}C]Nam to establish biodistribution and function [104]. Finally, [2′-^{2}H,*carbonyl*-^{13}C]NAR was synthesized and compared with [2′-^{2}H, ^{18}O]NR in metabolic fluxes and organelle transport experiments [34,40].

Conclusion

Overall, many chemical syntheses and chemoenzymatic syntheses have been developed to identify and trace the metabolites and precursors of NAD(P)(H) and quantify the metabolic distribution following supplementation. Current limitations associated with establishing a true representation of the vitamin B3 metabolome are associated with the breadth of molecules which this metabolome includes, the synthetic challenges associated with their individual preparation, the cost of the isotopically labeled reagents and the scale on which syntheses are carried out. However, these limitations appear to slowly fade as more efficient syntheses become available and enable cell-based kinetic studies and animal pharmacokinetics investigations. This review aimed to update our view of the vitamin B3 metabolome and the current chemical efforts undertaken in the field of NAD$^+$ biology to better understand its role in cellular biology and physiology.

Perspectives

1. Since NAD$^+$ seats at the cross-road of metabolism and cellular signaling, there is an urgent need to acquire a greater evidence-based understanding of vitamin B3 metabolism and of its role in health, diseases and ageing.
2. Increased access to fit-for-purpose chemical entities and biosynthetic intermediates has greatly enabled the recent discoveries in the NAD$^+$ field and facilitated translational research in ageing, metabolic diseases and nutrition.
3. As further analytical refinements are achieved, and analytical standards become more widely available, the cellular functions of endogenously generated vitamin B3 catabolites will come under greater scrutiny. Furthermore, as the functional co-dependence between the NAD(P)(H) pool and cofactors derived from vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B5 (pantothenate), vitamin B6 (pyridoxine) and vitamin B9 (folate) becomes more apparent, vitamin B-targeted metabolomics will offer new functional perspectives on the B-vitaminome.

Abbreviations

4PYR, *N*-ribosyl-3-carboxamide 4-pyridone; ADPR, adenosine diphosphoribose; ADPRP, adenosine diphosphoribose phosphate; N-Me-2PY, *N*-methyl-2-pyridone-5-carboxamide; *N*-Me-4PY, *N*-methyl-4-pyridone3-carboxamide; NA, nicotinic acid; NAAD, nicotinic acid adenine dinucleotide; NAADP, nicotinic acid adenine dinucleotide phosphate; NAD, adenine dinucleotide; NADH, 1,4-dihydronicotinamide adenine dinucleotide; NADP, nicotinamide adenine dinucleotide phosphate; NADS, nicotinamide Adenine dinucleotide synthase; Nam, nicotinamide; NAMN, nicotinic acid mononucleotide; NAPRT, Nicotinic acid phosphoribosyl transferase; NAR, nicotinic acid; NMN, nicotinamide mononucleotide; NMNAT, nicotinamide mononucleotide adenylyl transferase; NR, nicotinamide riboside; NRK, nicotinamide riboside kinase; PRPP, 5-phospho-1-pyrophosphoriboside.

Funding

M.M. received support from National Center for Complementary and Integrative Health R21 AT009908-01.

Competing Interests

The Authors declare that there are no competing interests associated with the manuscript.

References

1 Wolak, N., Zawrotniak, M., Gogol, M., Kozik, A. and Rapala-Kozik, M. (2017) Vitamins B1, B2, B3 and B9-occurrence, biosynthesis pathways and functions in human nutrition. *Mini. Rev. Med. Chem.* **17**, 1075–1111 https://doi.org/10.2174/1389557516666160725095729
2 Fricker, R.A., Green, E.L., Jenkins, S.I. and Griffin, S.M. (2018) The influence of nicotinamide on health and disease in the central nervous system. *Int. J. Tryptophan Res.* **11**, 1178646918776658 https://doi.org/10.1177/1178646918776658
3 Nikiforov, A., Kulikova, V. and Ziegler, M. (2015) The human NAD metabolome: functions, metabolism and compartmentalization. *Crit. Rev. Biochem. Mol. Biol.* **50**, 284–297 https://doi.org/10.3109/10409238.2015.1028612

4 Warszta, D., Nebel, M., Fliegert, R. and Guse, A.H. (2014) NAD derived second messengers: role in spontaneous diastolic Ca^{2+} transients in murine cardiac myocytes. *DNA Repair* **23**, 69–78 https://doi.org/10.1016/j.dnarep.2014.05.007
5 Ferrero, E., Lo Buono, N., Horenstein, A.L., Funaro, A. and Malavasi, F. (2014) The ADP-ribosyl cyclases–the current evolutionary state of the ARCs. *Front. Biosci.* **19**, 986–1002 https://doi.org/10.2741/4262
6 Maeta, A., Sano, M., Fukuwatari, T. and Shibata, K. (2014) Simultaneous measurement of nicotinamide and its catabolites, nicotinamide *N*-oxide, N^1-methyl-2-pyridone-5-carboxamide, and N^1-methyl-4-pyridone-3-carboxamide, in mice urine. *Biosci. Biotechnol. Biochem.* **78**, 1306–1309 https://doi.org/10.1080/09168451.2014.918495
7 Yoshino, J., Baur, J.A. and Imai, S.I. (2018) NAD^+ intermediates: the biology and therapeutic potential of NMN and NR. *Cell Metab.* **27**, 513–528 https://doi.org/10.1016/j.cmet.2017.11.002
8 Kulikova, V., Shabalin, K., Nerinovski, K., Dölle, C., Niere, M., Yakimov, A. et al. (2015) Generation, release, and uptake of the NAD precursor nicotinic acid riboside by human cells. *J. Biol. Chem.* **290**, 27124–27137 https://doi.org/10.1074/jbc.M115.664458
9 Verdin, E. (2015) NAD(+) in aging, metabolism, and neurodegeneration. *Science* **350**, 1208–1213 https://doi.org/10.1126/science.aac4854
10 Imai, S. and Guarente, L. (2014) NAD^+ and sirtuins in aging and disease. *Trends Cell Biol.* **24**, 464–471 https://doi.org/10.1016/j.tcb.2014.04.002
11 Dölle, C., Skoge, R., VanLinden, M. and Ziegler, M. (2013) NAD biosynthesis in humans–enzymes, metabolites and therapeutic aspects. *Curr. Top. Med. Chem.* **13**, 2907–2917 https://doi.org/10.2174/15680266113136660206
12 Menzies, K.J., Zhang, H., Katsyuba, E. and Auwerx, J. (2016) Protein acetylation in metabolism — metabolites and cofactors. *Nat. Rev. Endocrinol.* **12**, 43–60 https://doi.org/10.1038/nrendo.2015.181
13 Mouchiroud, L., Houtkooper, R.H. and Auwerx, J. (2013) NAD^+ metabolism: a therapeutic target for age-related metabolic disease. *Crit. Rev. Biochem. Mol. Biol.* **48**, 397–408 https://doi.org/10.3109/10409238.2013.789479
14 Zhang, H., Ryu, D., Wu, Y., Gariani, K., Wang, X., Luan, P. et al. (2016) NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice. *Science* **352**, 1436–1443 https://doi.org/10.1126/science.aaf2693
15 Mitchell, S.J., Bernier, M., Aon, M.A., Cortassa, S., Kim, E.Y., Fang, E.F. et al. (2018) Nicotinamide improves aspects of healthspan, but not lifespan, in mice. *Cell Metab.* **27**, 667–676.e4 https://doi.org/10.1016/j.cmet.2018.02.001
16 Berger, F., Ramirez-Hernandez, M.H. and Ziegler, M. (2004) The new life of a centenarian: signalling functions of NAD(P). *Trends Biochem. Sci.* **29**, 111–118 https://doi.org/10.1016/j.tibs.2004.01.007
17 Hill, L.J. and Williams, A.C. (2017) Meat intake and the dose of vitamin B3 — nicotinamide: cause of the causes of disease transitions, health divides, and health futures? *Int. J. Tryptophan. Res.* **10**, 1178646917704662 https://doi.org/10.1177/1178646917704662
18 Savvidou, S. (2014) Pellagra: a non-eradicated old disease. *Clin. Pract.* **4**, 637 https://doi.org/10.4081/cp.2014.637
19 Li, R., Yu, K., Wang, Q., Wang, L., Mao, J. and Qian, J. (2016) Pellagra secondary to medication and alcoholism: a case report and review of the literature. *Nutr. Clin. Pract.* **31**, 785–788 https://doi.org/10.1177/0884533616660991
20 Terada, N., Kinoshita, K., Taguchi, S. and Tokuda, Y. (2015) Wernicke encephalopathy and pellagra in an alcoholic and malnourished patient. *BMJ Case Rep.* **2015**, bcr2015209412 https://doi.org/10.1136/bcr-2015-209412
21 Crook, M.A. (2014) The importance of recognizing pellagra (niacin deficiency) as it still occurs. *Nutrition* **30**, 729–730 https://doi.org/10.1016/j.nut.2014.03.004
22 Garrido, A. and Djouder, N. (2017) NAD^+ deficits in age-related diseases and cancer. *Trends Cancer* **3**, 593–610 https://doi.org/10.1016/j.trecan.2017.06.001
23 Srivastava, S. (2016) Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders. *Clin. Transl. Med.* **5**, 25 https://doi.org/10.1186/s40169-016-0104-7
24 Mukherjee, S., Chellappa, K., Moffitt, A., Ndungu, J., Dellinger, R.W., Davis, J.G. et al. (2017) Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration. *Hepatology* **65**, 616–630 https://doi.org/10.1002/hep.28912
25 Hershberger, K.A., Martin, A.S. and Hirschey, M.D. (2017) Role of NAD^+ and mitochondrial sirtuins in cardiac and renal diseases. *Nat. Rev. Nephrol.* **13**, 213–225 https://doi.org/10.1038/nrneph.2017.5
26 Bonkowski, M.S. and Sinclair, D.A. (2016) Slowing ageing by design: the rise of NAD^+ and sirtuin-activating compounds. *Nat. Rev. Mol. Cell Biol.* **17**, 679–690 https://doi.org/10.1038/nrm.2016.93
27 Belenky, P., Bogan, K.L. and Brenner, C. (2007) NAD^+ metabolism in health and disease. *Trends Biochem. Sci.* **32**, 12–19 https://doi.org/10.1016/j.tibs.2006.11.006
28 Katsyuba, E. and Auwerx, J. (2017) Modulating NAD^+ metabolism, from bench to bedside. *EMBO J.* **36**, 2670–2683 https://doi.org/10.15252/embj.201797135
29 Chiarugi, A., Dölle, C., Felici, R. and Ziegler, M. (2012) The NAD metabolome–a key determinant of cancer cell biology. *Nat. Rev. Cancer* **12**, 741–752 https://doi.org/10.1038/nrc3340
30 VanLinden, M.R., Dölle, C., Pettersen, I.K.N., Kulikova, V.A., Niere, M., Agrimi, G. et al. (2015) Subcellular distribution of NAD^+ between cytosol and mitochondria determines the metabolic profile of human cells. *J. Biol. Chem.* **290**, 27644–27659 https://doi.org/10.1074/jbc.M115.654129
31 Gazzaniga, F., Stebbins, R., Chang, S.Z., McPeek, M.A. and Brenner, C. (2009) Microbial NAD metabolism: lessons from comparative genomics. *Microbiol. Mol. Biol. Rev.* **73**, 529–541 https://doi.org/10.1128/MMBR.00042-08
32 Gerdes, S.Y., Scholle, M.D., D'Souza, M., Bernal, A., Baev, M.V., Farrell, M. et al. (2002) From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. *J. Bacteriol.* **184**, 4555–4572 https://doi.org/10.1128/JB.184.16.4555-4572.2002
33 Bi, J., Wang, H. and Xie, J. (2011) Comparative genomics of NAD(P) biosynthesis and novel antibiotic drug targets. *J. Cell Physiol.* **226**, 331–340 https://doi.org/10.1002/jcp.22419
34 Liu, L., Su, X., Quinn, W.J., Hui, S., Krukenberg, K., Frederick, D.W. et al. (2018) Quantitative analysis of NAD synthesis-breakdown fluxes. *Cell Metab.* **27**, 1067–1080.e5 https://doi.org/10.1016/j.cmet.2018.03.018
35 Mori, V., Amici, A., Mazzola, F., Di Stefano, M., Conforti, L., Magni, G. et al. (2014) Metabolic profiling of alternative NAD biosynthetic routes in mouse tissues. *PLoS ONE* **9**, e113939 https://doi.org/10.1371/journal.pone.0113939
36 Shibata, K., Kobayashi, R. and Fukuwatari, T. (2015) Vitamin B1 deficiency inhibits the increased conversion of tryptophan to nicotinamide in severe food-restricted rats. *Biosci. Biotechnol. Biochem.* **79**, 103–108 https://doi.org/10.1080/09168451.2014.962473

37 Majewski, M., Kozlowska, A., Thoene, M., Lepiarczyk, E. and Grzegorzewski, W.J. (2016) Overview of the role of vitamins and minerals on the kynurenine pathway in health and disease. *J. Physiol. Pharmacol.* **67**, 3–19 PMID:27010891
38 Jacobson, E.L., Kim, H., Kim, M. and Jacobson, M.K. (2012) Niacin: vitamin and antidyslipidemic drug. *Subcell. Biochem.* **56**, 37–47 https://doi.org/10.1007/978-94-007-2199-9_3
39 Tempel, W., Rabeh, W.M., Bogan, K.L., Belenky, P., Wojcik, M., Seidle, H.F. et al. (2007) Nicotinamide riboside kinase structures reveal new pathways to NAD^+. *PLoS Biol.* **5**, e263 https://doi.org/10.1371/journal.pbio.0050263
40 Davila, A., Liu, L., Chellappa, K., Redpath, P., Nakamaru-Ogiso, E., Paolella, L.M. et al. (2018) Nicotinamide adenine dinucleotide is transported into mammalian mitochondria. *eLife* **7**, e33246 https://doi.org/10.7554/eLife.33246
41 Zhang, D.X., Zhang, J.-P., Hu, J.-Y. and Huang, Y.-S. (2016) The potential regulatory roles of NAD(+) and its metabolism in autophagy. *Metabolism* **65**, 454–462 https://doi.org/10.1016/j.metabol.2015.11.010
42 Tong, L. and Denu, J.M. (2010) Function and metabolism of sirtuin metabolite O-acetyl-ADP-ribose. *Biochim. Biophys. Acta* **1804**, 1617–1625 https://doi.org/10.1016/j.bbapap.2010.02.007
43 Long, A., Klimova, N. and Kristian, T. (2017) Mitochondrial NUDIX hydrolases: a metabolic link between NAD catabolism, GTP and mitochondrial dynamics. *Neurochem. Int.* **109**, 193–201 https://doi.org/10.1016/j.neuint.2017.03.009
44 Koch-Nolte, F., Fischer, S., Haag, F. and Ziegler, M. (2011) Compartmentation of NAD^+-dependent signalling. *FEBS Lett.* **585**, 1651–1656 https://doi.org/10.1016/j.febslet.2011.03.045
45 Camacho-Pereira, J., Tarragó, M.G., Chini, C.C.S., Nin, V., Escande, C., Warner, G.M. et al. (2016) CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. *Cell Metab.* **23**, 1127–1139 https://doi.org/10.1016/j.cmet.2016.05.006
46 Cohen, M.S. and Chang, P. (2018) Insights into the biogenesis, function, and regulation of ADP-ribosylation. *Nat. Chem. Biol.* **14**, 236–243 https://doi.org/10.1038/nchembio.2568
47 Aravind, L., Zhang, D., de Souza, R.F., Anand, S. and Iyer, L.M. (2015) The natural history of ADP-ribosyltransferases and the ADP-ribosylation system. *Curr. Top. Microbiol. Immunol.* **384**, 3–32 https://doi.org/10.1007/82_2014_414
48 Leslie Pedrioli, D.M., Leutert, M., Bilan, V., Nowak, K., Gunasekera, K., Ferrari, E. et al. (2018) Comprehensive ADP-ribosylome analysis identifies tyrosine as an ADP-ribose acceptor site. *EMBO Rep.* **19**, e45310 https://doi.org/10.15252/embr.201745310
49 Chen, B., Zang, W., Wang, J., Huang, Y., He, Y., Yan, L. et al. (2015) The chemical biology of sirtuins. *Chem. Soc. Rev.* **44**, 5246–5264 https://doi.org/10.1039/C4CS00373J
50 Chini, C.C.S., Tarrago, M.G. and Chini, E.N. (2017) NAD and the aging process: role in life, death and everything in between. *Mol. Cell Endocrinol.* **455**, 62–74 https://doi.org/10.1016/j.mce.2016.11.003
51 Calcraft, P.J., Ruas, M., Pan, Z., Cheng, X., Arredouani, A., Hao, X. et al. (2009) NAADP mobilizes calcium from acidic organelles through two-pore channels. *Nature* **459**, 596–600 https://doi.org/10.1038/nature08030
52 Lee, H.C. (2012) Cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) as messengers for calcium mobilization. *J. Biol. Chem.* **287**, 31633–31640 https://doi.org/10.1074/jbc.R112.349464
53 Opitz, C.A. and Heiland, I. (2015) Dynamics of NAD-metabolism: everything but constant. *Biochem. Soc. Trans.* **43**, 1127–1132 https://doi.org/10.1042/BST20150133
54 Dolle, C., Rack, J.G. and Ziegler, M. (2013) NAD and ADP-ribose metabolism in mitochondria. *FEBS J.* **280**, 3530–3541 https://doi.org/10.1111/febs.12304
55 Kasamatsu, A., Nakao, M., Smith, B.C., Comstock, L.R., Ono, T., Kato, J. et al. (2011) Hydrolysis of *O*-acetyl-ADP-ribose isomers by ADP-ribosylhydrolase 3. *J. Biol. Chem.* **286**, 21110–21117 https://doi.org/10.1074/jbc.M111.237636
56 Wei, H. and Yu, X. (2016) Functions of PARylation in DNA damage repair pathways. *Genomics Proteomics Bioinformatics* **14**, 131–139 https://doi.org/10.1016/j.gpb.2016.05.001
57 Gupte, R., Liu, Z. and Kraus, W.L. (2017) PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. *Genes Dev.* **31**, 101–126 https://doi.org/10.1101/gad.291518.116
58 Drenichev, M.S. and Mikhailov, S.N. (2015) Poly(ADP-ribose)—a unique natural polymer structural features, biological role and approaches to the chemical synthesis. *Nucleosides Nucleotides Nucleic Acids* **34**, 258–276 https://doi.org/10.1080/15257770.2014.984073
59 Jones, K.M. (1959) The mechanism of nicotinuric acid synthesis. *Biochem. J.* **73**, 714–719 https://doi.org/10.1042/bj0730714
60 Shibata, K., Fukuwatari, T. and Suzuki, C. (2014) Pharmacological doses of nicotinic acid and nicotinamide are independently metabolized in rats. *J. Nutr. Sci. Vitaminol.* **60**, 86–93 https://doi.org/10.3177/jnsv.60.86
61 Nomura, K., Shin, M., Sano, K., Umezawa, C. and Shimada, T. (1983) Nicotinamide *N*-oxide formation by rat liver microsomes. *Biochem. Pharmacol.* **32**, 934–936 https://doi.org/10.1016/0006-2952(83)90603-2
62 Kraus, D., Yang, Q., Kong, D., Banks, A.S., Zhang, L., Rodgers, J.T. et al. (2014) Nicotinamide *N*-methyltransferase knockdown protects against diet-induced obesity. *Nature* **508**, 258–262 https://doi.org/10.1038/nature13198
63 Hong, S., Moreno-Navarrete, J.M., Wei, X., Kikukawa, Y., Tzameli, I., Prasad, D. et al. (2015) Nicotinamide *N*-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. *Nat. Med.* **21**, 887–894 https://doi.org/10.1038/nm.3882
64 Zhou, J., Chan, L. and Zhou, S. (2012) Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease. *Curr. Med. Chem.* **19**, 3523–3531 https://doi.org/10.2174/092986712801323171
65 Baspinar, B., Eskici, G. and Ozcelik, A.O. (2017) How coffee affects metabolic syndrome and its components. *Food Funct.* **8**, 2089–2101 https://doi.org/10.1039/C7FO00388A
66 Stretch, C., Eastman, T., Mandal, R., Eisner, R., Wishart, D.S., Mourtzakis, M. et al. (2012) Prediction of skeletal muscle and fat mass in patients with advanced cancer using a metabolomic approach. *J. Nutr.* **142**, 14–21 https://doi.org/10.3945/jn.111.147751
67 Lenglet, A., Liabeuf, S., Bodeau, S., Louvet, L., Mary, A., Boullier, A. et al. (2016) *N*-methyl-2-pyridone-5-carboxamide (2PY)-major metabolite of nicotinamide: an update on an old uremic toxin. *Toxins* **8**, E339 https://doi.org/10.3390/toxins8110339
68 Kremer, J.I., Gömpel, K., Bakuradze, T., Eisenbrand, G. and Richling, E. (2018) Urinary excretion of niacin metabolites in humans after coffee consumption. *Mol. Nutr. Food Res.* **62**, e1700735 https://doi.org/10.1002/mnfr.201700735

69 Shibata, K., Morita, N., Shibata, Y. and Fukuwatari, T. (2013) Enzymes that control the conversion of L-tryptophan-nicotinamide and the urinary excretion ratio (N^1)-methyl-2-pyridone-5-carboxamide+N^1-methyl-4-pyridone-3-carboxamide)/N^1-methylnicotinamide in mice. *Biosci. Biotechnol. Biochem.* **77**, 2105–2111 https://doi.org/10.1271/bbb.130467

70 Shibata, K. and Matsuo, H. (1989) Correlation between niacin equivalent intake and urinary excretion of its metabolites, *N*-methylnicotinamide, *N*-methyl-2-pyridone-5-carboxamide, and *N*-methyl-4-pyridone-3-carboxamide, in humans consuming a self-selected food. *Am. J. Clin. Nutr.* **50**, 114–119 https://doi.org/10.1093/ajcn/50.1.114

71 Rutkowski, B., Slominska, E., Szolkiewicz, M., Smolenski, R.T., Striley, C., Rutkowski, P. et al. (2003) *N*-methyl-2-pyridone-5-carboxamide: a novel uremic toxin? *Kidney Int. Suppl.* **63**, S19–S21 https://doi.org/10.1046/j.1523-1755.63.s84.36.x

72 Schmeisser, K., Mansfeld, J., Kuhlow, D., Weimer, S., Priebe, S., Heiland, I. et al. (2013) Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. *Nat. Chem. Biol.* **9**, 693–700 https://doi.org/10.1038/nchembio.1352

73 Rutkowski, P., Slominska, E.M., Wołyniec, W., Smoleński, R.T., Szolkiewicz, M., Świerczyński, J. et al. (2008) Nicotinamide metabolites accumulate in the tissues of uremic rats. *J. Ren. Nutr.* **18**, 56–59 https://doi.org/10.1053/j.jrn.2007.10.012

74 Slominska, E.M., Kowalik, K., Smolenski, R.T., Szolkiewicz, M., Rutkowski, P., Rutkowski, B. et al. (2006) Accumulation of poly(ADP-ribose) polymerase inhibitors in children with chronic renal failure. *Pediatr. Nephrol.* **21**, 800–806 https://doi.org/10.1007/s00467-006-0072-z

75 Slominska, E.M., Smolenski, R.T., Osborne, F., Swierczynski, J. and Yacoub, M.H. (2005) The effect of *N*-methyl-2-pyridone-5-carboxamide—a nicotinamide catabolite on poly ADP-rybosylation and oxidative stress injury in endothelial cells. *Nucleosides Nucleotides Nucleic Acids* **24**, 259–262 https://doi.org/10.1081/NCN-59697

76 Pelikant-Małecka, I., Sielicka, A., Kaniewska, E., Smoleński, R.T. and Słomińska, E.M. (2014) 4-Pyridone-3-carboxamide-1β-D-ribonucleoside metabolism in endothelial cells and its impact on cellular energetic balance. *Nucleosides Nucleotides Nucleic Acids* **33**, 338–341 https://doi.org/10.1080/15257770.2014.889303

77 Pelikant-Małecka, I., Sielicka, A., Kaniewska, E., Smoleński, R.T. and Słomińska, E.M. (2016) Influence of 4-pyridone-3-carboxamide-1β-D-ribonucleoside (4PYR) on activities of extracellular enzymes in endothelial human cells. *Nucleosides Nucleotides Nucleic Acids* **35**, 732–736 https://doi.org/10.1080/15257770.2016.1174263

78 Synesiou, E., Fairbanks, L.D., Simmonds, H.A., Slominska, E.M., Smolenski, R.T. and Carrey, E.A. (2011) 4-Pyridone-3-carboxamide-1-beta-D-ribonucleoside triphosphate (4PyTP), a novel NAD metabolite accumulating in erythrocytes of uremic children: a biomarker for a toxic NAD analogue in other tissues? *Toxins* **3**, 520–537 https://doi.org/10.3390/toxins3060520

79 Slominska, E.M., Carrey, E.A., Foks, H., Orlewska, C., Wieczerzak, E., Sowinski, P. et al. (2006) A novel nucleotide found in human erythrocytes, 4-pyridone-3-carboxamide-1-beta-D-ribonucleoside triphosphate. *J. Biol. Chem.* **281**, 32057–32064 https://doi.org/10.1074/jbc.M607514200

80 Slominska, E.M., Orlewska, C., Yuen, A., Osman, L., Romaszko, P., Sokolowska, E. et al. (2008) Metabolism of 4-pyridone-3-carboxamide-1-beta-D-ribonucleoside triphosphate and its nucleoside precursor in the erythrocytes. *Nucleosides Nucleotides Nucleic Acids* **27**, 830–834 https://doi.org/10.1080/15257770802146452

81 Romaszko, P., Slominska, E.M. and Smolenski, R.T. (2014) Effect of 4-pyridone-3-carboxamide ribonucleoside (4PYR)-potential cardiovascular toxin in perfused rat heart. *Nucleosides Nucleotides Nucleic Acids* **33**, 333–337 https://doi.org/10.1080/15257770.2013.872793

82 Romaszko, P., Slominska, E.M., Orlewska, C., Lipinski, M. and Smolenski, R.T. (2011) Metabolism of 4-pyridone-3-carboxamide-1-beta-D-ribonucleoside (4PYR) in rodent tissues and in vivo. *Mol. Cell Biochem.* **351**, 143–148 https://doi.org/10.1007/s11010-011-0721-9

83 Hanukoglu, I. (2017) Conservation of the enzyme-coenzyme interfaces in FAD and NADP binding adrenodoxin reductase—a ubiquitous enzyme. *J. Mol. Evol.* **85**, 205–218 https://doi.org/10.1007/s00239-017-9821-9

84 de Rosa, M., Pennati, A., Pandini, V., Monzani, E., Zanetti, G. and Aliverti, A. (2007) Enzymatic oxidation of $NADP^+$ to its 4-oxo derivative is a side-reaction displayed only by the adrenodoxin reductase type of ferredoxin-$NADP^+$ reductases. *FEBS J.* **274**, 3998–4007 https://doi.org/10.1111/j.1742-4658.2007.05934.x

85 Bossi, R.T., Iverti, A., Raimondi, D., Fischer, F., Zanetti, G., Ferrari, D. et al. (2002) A covalent modification of $NADP^+$ revealed by the atomic resolution structure of FprA, a *Mycobacterium tuberculosis* oxidoreductase. *Biochemistry* **41**, 8807–8818 https://doi.org/10.1021/bi025858a

86 Pelikant-Malecka, I., Kaniewska-Bednarczuk, E., Szrok, S., Sielicka, A., Sledzinski, M., Orlewska, C. et al. (2017) Metabolic pathway of 4-pyridone-3-carboxamide-1β-D-ribonucleoside and its effects on cellular energetics. *Int. J. Biochem. Cell Biol.* **88**, 31–43 https://doi.org/10.1016/j.biocel.2017.03.012

87 Becker-Kettern, J., Paczia, N., Conrotte, J.-F., Zhu, C., Fiehn, O., Jung, P.P. et al. (2018) NAD(p)HX repair deficiency causes central metabolic perturbations in yeast and human cells. *FEBS J.* **285**, 3376–3401 https://doi.org/10.1111/febs.14631

88 Marbaix, A.Y., Tyteca, D., Niehaus, T.D., Hanson, A.D., Linster, C.L. and Van Schaftingen, E. (2014) Occurrence and subcellular distribution of the NADPHX repair system in mammals. *Biochem. J.* **460**, 49–58 https://doi.org/10.1042/BJ20131482

89 Hoag, M.R., Roman, J., Beaupre, B.A., Silvaggi, N.R. and Moran, G.R. (2015) Bacterial renalase: structure and kinetics of an enzyme with 2- and 6-dihydro-beta-NAD(P) oxidase activity from *Pseudomonas phaseolicola*. *Biochemistry* **54**, 3791–3802 https://doi.org/10.1021/acs.biochem.5b00451

90 Oppenheimer, N.J. and Kaplan, N.O. (1975) The alpha beta epimerization of reduced nicotinamide adenine dinucleotide. *Arch. Biochem. Biophys.* **166**, 526–535 https://doi.org/10.1016/0003-9861(75)90416-6

91 Klemm, A., Steiner, T., Cumme, G.A. and Horn, A. (1993) Determination, purification, and characterization of alpha-NADH. *Anal. Biochem.* **212**, 375–380 https://doi.org/10.1006/abio.1993.1343

92 Beaupre, B.A., Hoag, M.R., Carmichael, B.R. and Moran, G.R. (2013) Kinetics and equilibria of the reductive and oxidative half-reactions of human renalase with alpha-NADPH. *Biochemistry* **52**, 8929–8937 https://doi.org/10.1021/bi401185m

93 Moran, G.R. and Hoag, M.R. (2017) The enzyme: renalase. *Arch. Biochem. Biophys.* **632**, 66–76 https://doi.org/10.1016/j.abb.2017.05.015

94 Trammell, S.A., Schmidt, M.S., Weidemann, B.J., Redpath, P., Jaksch, F., Dellinger, R.W. et al. (2016) Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. *Nat. Commun.* **7**, 12948 https://doi.org/10.1038/ncomms12948

95 Dellinger, R.W., Santos, S.R., Morris, M., Evans, M., Alminana, D., Guarente, L. et al. (2017) Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD^+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. *NPJ Aging Mech. Dis.* **3**, 17 https://doi.org/10.1038/s41514-017-0016-9

96 Martens, C.R., Denman, B.A., Mazzo, M.R., Armstrong, M.L., Reisdorph, N., McQueen, M.B. et al. (2018) Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD^+ in healthy middle-aged and older adults. *Nat. Commun.* **9**, 1286 https://doi.org/10.1038/s41467-018-03421-7
97 Okamoto, H. and Hayaishi, O. (1967) Flavin adenine dinucleotide requirement for kynurenine hydroxylase of rat liver mitochondria. *Biochem. Biophys. Res. Commun.* **29**, 394–399 https://doi.org/10.1016/0006-291X(67)90469-X
98 Dalgliesh, C.E., Knox, W.E. and Neuberger, A. (1951) Intermediary metabolism of tryptophan. *Nature* **168**, 20 https://doi.org/10.1038/168020a0
99 Hara, N., Yamada, K., Shibata, T., Osago, H., Hashimoto, T. and Tsuchiya, M. (2007) Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. *J. Biol. Chem.* **282**, 24574–24582 https://doi.org/10.1074/jbc.M610357200
100 Rongvaux, A., Shea, R., Mulks, M., Gigot, D., Urbain, J., Leo, O. et al. (2002) Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. *Eur. J. Immunol.* **32**, 3225–3234 https://doi.org/10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L
101 Revollo, J.R., Grimm, A.A. and Imai, S. (2004) The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. *J. Biol. Chem.* **279**, 50754–50763 https://doi.org/10.1074/jbc.M408388200
102 van der Veer, E., Nong, Z., O'Neil, C., Urquhart, B., Freeman, D. and Pickering, J.G. (2005) Pre-B-cell colony-enhancing factor regulates NAD^+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. *Circ. Res.* **97**, 25–34 https://doi.org/10.1161/01.RES.0000173298.38808.27
103 Fletcher, R.S., Ratajczak, J., Doig, C.L., Oakey, L.A., Callingham, R., Da Silva Xavier, G. et al. (2017) Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells. *Mol. Metab.* **6**, 819–832 https://doi.org/10.1016/j.molmet.2017.05.011
104 Frederick, D.W., Loro, E., Liu, L., Davila, A., Chellappa, K., Silverman, I.M. et al. (2016) Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle. *Cell Metab.* **24**, 269–282 https://doi.org/10.1016/j.cmet.2016.07.005
105 Mills, K.F., Yoshida, S., Stein, L.R., Grozio, A., Kubota, S., Sasaki, Y. et al. (2016) Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. *Cell Metab.* **24**, 795–806 https://doi.org/10.1016/j.cmet.2016.09.013
106 Uddin, G.M., Youngson, N.A., Doyle, B.M., Sinclair, D.A. and Morris, M.J. (2017) Nicotinamide mononucleotide (NMN) supplementation ameliorates the impact of maternal obesity in mice: comparison with exercise. *Sci. Rep.* **7**, 15063 https://doi.org/10.1038/s41598-017-14866-z
107 Ratajczak, J., Joffraud, M., Trammell, S.A.J., Ras, R., Canela, N., Boutant, M. et al. (2016) NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. *Nat. Commun.* **7**, 13103 https://doi.org/10.1038/ncomms13103
108 Kornberg, A. (1948) The participation of inorganic pyrophosphate in the reversible enzymatic synthesis of diphosphopyridine nucleotide. *J. Biol. Chem.* **176**, 1475 PMID:18098602
109 Berger, F., Lau, C., Dahlmann, M. and Ziegler, M. (2005) Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. *J. Biol. Chem.* **280**, 36334–36341 https://doi.org/10.1074/jbc.M508660200
110 Zerez, C.R., Wong, M.D. and Tanaka, K.R. (1990) Partial purification and properties of nicotinamide adenine dinucleotide synthetase from human erythrocytes: evidence that enzyme activity is a sensitive indicator of lead exposure. *Blood* **75**, 1576–1582 PMID:2107886
111 Pollak, N., Niere, M. and Ziegler, M. (2007) NAD kinase levels control the NADPH concentration in human cells. *J. Biol. Chem.* **282**, 33562–33571 https://doi.org/10.1074/jbc.M704442200
112 Zhang, L.Q., Van Haandel, L., Xiong, M., Huang, P., Heruth, D.P., Bi, C. et al. (2017) Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase. *Cell Death Dis.* **8**, e2705 https://doi.org/10.1038/cddis.2017.132
113 Trammell, S.A., Yu, L., Redpath, P., Migaud, M.E. and Brenner, C. (2016) Nicotinamide riboside is a major NAD^+ precursor vitamin in cow milk. *J. Nutr.* **146**, 957–963 https://doi.org/10.3945/jn.116.230078
114 Ummarino, S., Mozzon, M., Zamporlini, F., Amici, A., Mazzola, F., Orsomando, G. et al. (2017) Simultaneous quantitation of nicotinamide riboside, nicotinamide mononucleotide and nicotinamide adenine dinucleotide in milk by a novel enzyme-coupled assay. *Food Chem.* **221**, 161–168 https://doi.org/10.1016/j.foodchem.2016.10.032
115 Cooper, D.L., Murrell, D.E., Roane, D.S. and Harirforoosh, S. (2015) Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery. *Int. J. Pharm.* **490**, 55–64 https://doi.org/10.1016/j.ijpharm.2015.05.024
116 Kaplan, N.O. and Stolzenbach, F.E. (1957) [129] Preparation of DPN derivatives and analogs. *Methods Enzymol.* **3**, 899–905 https://doi.org/10.1016/S0076-6879(57)03473-4
117 Saunders, P.P., Tan, M.T., Spindler, C.D. and Robins, R.K. (1989) Phosphorylation of 3-deazaguanosine by nicotinamide riboside kinase in Chinese hamster ovary cells. *Cancer Res.* **49**, 6593–6599 PMID:2555047
118 Velasquez, J.E.C., Green, P.R. and Wos, J.A. (2017) *Method For Preparing Nicotinamide Riboside*, Procter & Gamble Company, Cincinnati, OH, U.S.A.
119 Lee, J., Churchil, H., Choi, W.-B., Lynch, J.E., Roberts, F.E., Volante, R.P. et al. (1999) A chemical synthesis of nicotinamide adenine dinucleotide (NAD^+). *Chem. Commun.* **8**, 729–730 https://doi.org/10.1039/a809930h
120 Jeck, R. and Woenckhaus, C. (1980) Simple methods for preparing nicotinamide mononucleotide and related analogs. *Methods Enzymol.* **66**, 62–70 https://doi.org/10.1016/0076-6879(80)66439-8
121 Jeck, R., Heik, P. and Woenckhaus, C. (1974) Simple methods of preparing nicotinamide mononucleotide. *FEBS Lett.* **42**, 161–164 https://doi.org/10.1016/0014-5793(74)80776-3
122 Martínez-Moñino, A.-B., Zapata-Pérez, R., García-Saura, A.-G., Cabanes, J. and Sánchez-Ferrer, Á. (2017) A new cross-linked enzyme aggregate biocatalyst for NAD^+-booster production. *RSC Adv.* **7**, 14272–14278 https://doi.org/10.1039/C7RA00505A
123 Haynes, L.J. and Todd, A.R. (1950) 66. Codehydrogenases. Part I. The synthesis of dihydronicotinamide-D-ribofuranoside [N-D-ribofuranosidyl-1: 2(or 6)-dihydronicotinamide]. *J. Chem. Soc.* 303–308 https://doi.org/10.1039/jr9500000303
124 Haynes, L.J., Hughes, N.A., Kenner, G.W. and Todd, A. (1957) 734. Codehydrogenases. Part II. A synthesis of nicotinamide nucleotide. *J. Chem. Soc.* 3727–3732 https://doi.org/10.1039/JR9570003727
125 Ness, R.K., Diehl, H.W. and Fletcher, H.G. (1954) New benzoyl derivatives of D-ribofuranose and aldehydo-D-ribose. The preparation of crystalline 2,3,5-Tri-*O*-benzoyl-β-D-ribose from D-Ribose1. *J. Am. Chem. Soc.* **76**, 763–767 https://doi.org/10.1021/ja01632a038
126 Vorbrüggen, H. and Ruh-Pohlenz, C. (2004) *Synthesis of Nucleosides. Organic Reactions* https://doi.org/10.1002/0471264180.or055.01

127 Franchetti, P., Pasqualini, M., Petrelli, R., Ricciutelli, M., Vita, P. and Cappellacci, L. (2004) Stereoselective synthesis of nicotinamide β-riboside and nucleoside analogs. *Bioorg. Med. Chem. Lett.* **14**, 4655–4658 https://doi.org/10.1016/j.bmcl.2004.06.093
128 Tanimori, S., Ohta, T. and Kirihata, M. (2002) An efficient chemical synthesis of nicotinamide riboside (NAR) and analogues. *Bioorg. Med. Chem. Lett.* **12**, 1135–1137 https://doi.org/10.1016/S0960-894X(02)00125-7
129 Yang, T., Chan, N.Y. and Sauve, A.A. (2007) Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells. *J. Med. Chem.* **50**, 6458–6461 https://doi.org/10.1021/jm701001c
130 Zhang, N. and Sauve, A.A. (2017) Synthesis of β-nicotinamide riboside using an efficient two-step methodology. *Curr. Protoc. Nucleic Acid Chem.* **71**, 14.14.1–14.14.9 https://doi.org/10.1002/cpnc.43
131 Szcepankiewicz, B.P.F., Koppetsch, K. and Perni, R.B. (2015) Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof. U.S. Pat. WO/2015/186114
132 Fouquerel, E., Goellner, E.M., Yu, Z., Gagné, J.-P., Barbi de Moura, M., Feinstein, T. et al. (2014) ARTD1/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD^+ depletion. *Cell Rep.* **8**, 1819–1831 https://doi.org/10.1016/j.celrep.2014.08.036
133 Marie Migaud, P.R., Crossey, K. and Doherty, M. (2016) Methods of preparing nicotinamide riboside and derivatives thereof. U.S. Pat. 20160168184
134 Yang, A.S.F.S.M.Y. (2016) Syntheses, activities and methods of use of dihydronicotinamide riboside derivatives in PCT 15/744,602
135 Dellinger, R.M., Marie, E., Redpath, P., Rhonemus, T. and Cunningham, R. (2016) Nicotinic acid riboside or nicotinamide riboside composition, reduced derivatives thereof, and use thereof. U.S. Pat. PCT/US2016/022682
136 Normington, K.D.S., David, A., Livingston, D., McKearin, J.M., Szczepankiewicz, B. and Kremsky, J.N. (2017) Nicotinamide mononucleotide derivatives and their uses in WO/2017/024255
137 Eisner, U. and Kuthan, J. (1972) Chemistry of dihydropyridines. *Chem. Rev.* **72**, 1–42 https://doi.org/10.1021/cr60275a001
138 Stout, D.M. and Meyers, A.I. (1982) Recent advances in the chemistry of dihydropyridines. *Chem. Rev.* **82**, 223–243 https://doi.org/10.1021/cr00048a004
139 Silva, E.M.P., Varandas, P.A.M.M. and Silva, A.M.S. (2013) Developments in the synthesis of 1,2-dihydropyridines. *Synthesis* **45**, 3053–3089 https://doi.org/10.1055/s-0033-1338537
140 Sharma, V.K. and Singh, S.K. (2017) Synthesis, utility and medicinal importance of 1,2- & 1,4-dihydropyridines. *RSC Adv.* **7**, 2682–2732 https://doi.org/10.1039/C6RA24823C
141 Dutta, S.P., Crain, P.F., McCloskey, J.A. and Chheda, G.B. (1979) Isolation and characterization of 1-β-D-ribofuranosylpyridin-4-one-3-carboxamide from human urine. *Life Sci.* **24**, 1381–1388 https://doi.org/10.1016/0024-3205(79)90008-0
142 Lang, R., Wahl, A., Skurk, T., Yagar, E.F., Schmiech, L., Eggers, R. et al. (2010) Development of a hydrophilic liquid interaction chromatography–high-performance liquid chromatography–tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. *Anal. Chem.* **82**, 1486–1497 https://doi.org/10.1021/ac902616k
143 Lappin, G. (2015) A historical perspective on radioisotopic tracers in metabolism and biochemistry. *Bioanalysis* **7**, 531–540 https://doi.org/10.4155/bio.14.286
144 Kim, I.-Y., Suh, S.-H., Lee, I.-K. and Wolfe, R.R. (2016) Applications of stable, nonradioactive isotope tracers in in vivo human metabolic research. *Exp. Mol. Med.* **48**, e203 https://doi.org/10.1038/emm.2015.97
145 Jang, C., Chen, L. and Rabinowitz, J.D. (2018) Metabolomics and isotope tracing. *Cell* **173**, 822–837 https://doi.org/10.1016/j.cell.2018.03.055
146 Vella, A. and Rizza, R.A. (2009) Application of isotopic techniques using constant specific activity or enrichment to the study of carbohydrate metabolism. *Diabetes* **58**, 2168–2174 https://doi.org/10.2337/db09-0318
147 Satyanarayana, U. and Rao, B.S. (1983) In vivo conversion of tryptophan to nicotinic acid in rats studied by simultaneous incorporation of [3H]-tryptophan and [14C]-nicotinic acid into liver NAD and NADP. *Ann. Nutr. Metab.* **27**, 1–7 https://doi.org/10.1159/000176617
148 Sen, A., Stojkovic, V. and Kohen, A. (2012) Synthesis of radiolabeled nicotinamide cofactors from labeled pyridines: versatile probes for enzyme kinetics. *Anal. Biochem.* **430**, 123–129 https://doi.org/10.1016/j.ab.2012.08.012
149 Ueda, K., Yamamura, H. and Nishizuka, Y. (1971) [106] Preparation of labeled pyridine ribonucleotides and ribonucleosides. *Methods Enzymol.* **18**, 55–60 https://doi.org/10.1016/S0076-6879(71)18063-9
150 Friedmann, H.C. (1971) [105] Preparation of DPN^+ and NMN labeled with14C in the pyridine moiety. *Methods Enzymol.* **18**, 51–55 https://doi.org/10.1016/S0076-6879(71)18062-7
151 Williams, T.J., Zens, A.P., Wisowaty, J.C., Fisher, R.R., Dunlap, R.B., Bryson, T.A. et al. (1976) Nuclear magnetic resonance studies on pyridine dinucleotides. The pH dependence of the carbon-13 nuclear magnetic resonance of NAD^+ analogs. *Arch. Biochem. Biophys.* **172**, 490–501 https://doi.org/10.1016/0003-9861(76)90102-8
152 Oppenheimer, N.J. and Davidson, R.M. (1980) 15N nuclear magnetic resonance studies of [1-15N]nicotinamide adenine dinucleotides. *Org. Magn Res.* **13**, 14–16 https://doi.org/10.1002/mrc.1270130104
153 Ueda, K. and Yamamura, H. (1971) [107] Preparation of various labeled NAD's. *Methods Enzymol.* **18**, 60–67 https://doi.org/10.1016/S0076-6879(71)18064-0
154 Colowick, S.P. and Kaplan, N.O. (1957) [34] Preparation and analysis of labeled coenzymes. *Methods Enzymol.* **4**, 840–855 https://doi.org/10.1016/0076-6879(57)04082-3
155 Markham, K.A., Sikorski, R.S. and Kohen, A. (2004) Synthesis and utility of ^{14}C-labeled nicotinamide cofactors. *Anal. Biochem.* **325**, 62–67 https://doi.org/10.1016/j.ab.2003.10.027
156 Kasăsarov, L.B. and Moat, A.G. (1980) [18] Convenient method for enzymic synthesis of [^{14}C]nicotinamide riboside. *Methods Enzymol.* **66**, 120–122 https://doi.org/10.1016/0076-6879(80)66448-9
157 Cen, Y. and Sauve, A.A. (2010) Transition state of ADP-ribosylation of acetyllysine catalyzed by *Archaeoglobus fulgidus* Sir2 determined by kinetic isotope effects and computational approaches. *J. Am. Chem. Soc.* **132**, 12286–12298 https://doi.org/10.1021/ja910342d
158 Bull, H.G., Ferraz, J.P., Cordes, E.H., Ribbi, A. and Apitz-Castro, R. (1978) Concerning the mechanism of the enzymatic and nonenzymatic hydrolysis of nicotinamide nucleotide coenzymes. *J. Biol. Chem.* **253**, 5186–5192 PMID:209029
159 Rising, K.A. and Schramm, V.L. (1997) Transition state analysis of NAD^+ hydrolysis by the cholera toxin catalytic subunit. *J. Am. Chem. Soc.* **119**, 27–37 https://doi.org/10.1021/ja9621915

160 Berti, P.J., Blanke, S.R. and Schramm, V.L. (1997) Transition state structure for the hydrolysis of NAD^+ catalyzed by diphtheria toxin. *J. Am. Chem. Soc.* **119**, 12079–12088 https://doi.org/10.1021/ja971317a
161 Rising, K.A. and Schramm, V.L. (1994) Enzymic synthesis of NAD^+ with the specific incorporation of atomic labels. *J. Am. Chem. Soc.* **116**, 6531–6536 https://doi.org/10.1021/ja00094a006
162 Scheuring, J., Berti, P.J. and Schramm, V.L. (1998) Transition-state structure for the ADP-ribosylation of recombinant Giα1 subunits by pertussis toxin. *Biochemistry* **37**, 2748–2758 https://doi.org/10.1021/bi972594x
163 Tran, A., Yokose, R. and Cen, Y. (2018) Chemo-enzymatic synthesis of isotopically labeled nicotinamide riboside. *Org. Biomol. Chem.* **16**, 3662–3671 https://doi.org/10.1039/C8OB00552D
164 Lu, W., Wang, L., Chen, L., Hui, S. and Rabinowitz, J.D. (2018) Extraction and quantitation of nicotinamide adenine dinucleotide redox cofactors. *Antioxid. Redox Signal.* **28**, 167–179 https://doi.org/10.1089/ars.2017.7014
165 Yang, T. and Sauve, A.A. (2006) NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. *AAPS J.* **8**, E632–E643 https://doi.org/10.1208/aapsj080472